Media Coverage

Chronic medical issues are frustrating for both doctors and patients, who just want to feel better. Tammie Robie, 51, struggled for nearly 20 years with blood pressure that was resistant against multiple medications. She pushed through her days as a wife, mother, teacher and competitive runner. Dr. Sanjay Dixit, the medical director for Quest Diagnostics, said PA was considered uncommon for many years. “Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood,” he said. The adrenal glands are located on top of the kidneys. According to Dixit, the Endocrine Society recommended in 2025 that all patients with hypertension be evaluated for PA. He notes that nearly half of all adults, or nearly 120 million people, have high blood pressure.

Postpartum body odor and sweating are common and generally not a cause for concern. Hormonal changes, milk production, and excess fluid shedding contribute to postpartum body odor. Damian Pat Alagia III, MD, MS, MBA, medical director for women’s health at Quest Diagnostics, explains that a pregnant person gains up to 10 pounds of amniotic fluid, blood, and other fluids.“Once the baby is born, the fluid needs somewhere to go," Dr. Alagia adds. Because of this, postpartum parents often experience increased sweating. "This is the body’s way of flushing out these excess fluids.”

Primary aldosteronism (PA) is a serious condition that affects as many as 5 to 10 percent of adults with high blood pressure (BP). High BP is widely prevalent in the U.S., nearly half of all adults (almost 120 million individuals) have it. Yet, for many years, PA was considered uncommon. However, recent research shows PA is both prevalent and under-detected. Untreated, it significantly raises risk of heart attack, stroke, and kidney disease.

Alzheimer’s disease (AD) is the major cause of dementia worldwide that leads to morbidity, long term care utilization, and significant healthcare costs. Dr. Yonghong Li and his colleagues at Quest Diagnostics performed a study to determine the efficacy and cost-effectiveness of using blood-based biomarker as a triage in Alzheimer’s disease testing. Dr. Michael K. Racke, Medical Director of Neurology at Quest Diagnostics and a co-investigator of this study summarized their findings.

Early cancer detection once meant imaging, pathology, and a defined set of screening tests with established follow-up pathways. Today, circulating tumor DNA assays, minimal residual disease (MRD) testing, and multi-cancer early detection platforms are expanding what is possible, often faster than the health systems meant to operationalize them.Yuri Fesko, MD, Senior Vice President and Chief Medical Officer for Quest Diagnostics, sees both extraordinary promise and practical disconnect.

In this episode of the WHOOP Podcast, WHOOP Founder and CEO Will Ahmed sits down with Quest Diagnostics CEO Jim Davis to discuss the partnership behind WHOOP Advanced Labs. Will and Jim discuss how combining blood biomarkers with continuous physiological data is reshaping consumer health.

City of Hope is implementing the Haystack minimal residual disease (MRD) test from Quest Diagnostics for clinical trial participants with solid tumor cancers. The research aims to guide disease management for patients with breast, colorectal, ovarian, and prostate cancer.

Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing. Shares of the ​New Jersey-based company were up about 4% in early trading.

A blood test based from a South Baltimore lab is making treatment clearer for cancer patients. HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that conventional methods may miss. While it's been in development for many, many years, the test was made clinically available for oncologists and pharmaceutical partners in late 2024.

In this exclusive interview, Quest Diagnostics’ Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann.